Prophylactic treatment (primary prevention) | LVEF HASH(0x2fcb3a0) 35% and NYHA class II-III symptoms after myocardial infarction (HASH(0x2fcaf98) 40 days) |
LVEF HASH(0x2fcb3a0) 30% and NYHA class I symptoms after myocardial infarction (HASH(0x2fcaf98) 40 days) |
Nonsustained VT and LVEF HASH(0x2fcb3a0) 40% after myocardial infarction, as well as sustained VT or VF during electrophysiological examination |
LVEF HASH(0x2fcb3a0) 35% and NYHA class II-III symptoms or syncope in dilated cardiomyopathy |
If considered appropriate by a specialist physician in other structural heart diseases (e.g. hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy) and in inherited, potentially life-threatening ion-channel abnormalities (e.g. long QT syndrome, Brugada syndrome, catecholamine-sensitive polymorphic VT) |
Treatment post cardiac arrest (secondary prevention) | VT or VF induced cardiac arrest not due to a treatable or reversible cause, even if the heart is structurally normal |
Sustained VT in a patient with a structural heart disease, irrespective of the left ventricular function |
Unexplained syncope, as well as sustained VT or VF triggered during an electrophysiological examination |